Researchers at UB have developed a novel technology that is expected to have implications for research and treatment of tuberculosis and other lung diseases.
A group of young entrepreneurs led by Krishnan Chakravarthy, an MD/PhD candidate in the school’s MD-PhD Program, has launched NanoAxis, a new research and development company headquartered in Getzville, New York.